Drug Profile
Research programme: lipocalin derivatives - Pieris Pharmaceuticals/Stelis Biopharma
Alternative Names: SBL 011Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator Pieris
- Developer Pieris Pharmaceuticals; Stelis Biopharma
- Class Eye disorder therapies; Lipocalins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Eye-disorders in India
- 09 Mar 2018 Research programme: lipocalin derivatives - Pieris Pharmaceuticals/Stelis Biopharma is available for licensing as of 09 Mar 2018. http://stelis.com/ (Stelis Biopharma website, March 2018)
- 07 Mar 2018 Preclinical trials in Eye disorders in India (unspecified route) (Stelis Biopharma pipeline, March 2018)